 |
200 Diseases |  |
167 Trials |
|
167 Trials |  |
21364 News |  |
| «12345678910111213...227228» |
- Humira (adalimumab) / AbbVie
PREDICTIVE FACTORS OF RESPONSE TO ADALIMUMAB ONCE WEEKLY AMONG PORTUGUESE PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLARTHRITIS AND PSORIATIC ARTHRITIS: A REAL-WORLD EVIDENCE STUDY () - May 28, 2025 - Abstract #EULAR2025EULAR_3477;
Conversely, the presence of ACPA in RA significantly reduced response probability, likely reflecting its known association with more severe disease and poorer prognosis. A small inverse association between ESR and response was observed in RA (multivariate analysis) and PsA (univariate analysis), suggesting its potential utility in risk stratification: higher ESR at baseline, indicative of greater systemic inflammation, may predict decreased odds of achieving clinical response to ADA ow.
- PATIENTS' ACCEPTANCE OF THE EXPERIENCE SAMPLING METHOD APPLIED VIA A MOBILE HEALTH APPLICATION TO STUDY PATIENT-REPORTED REAL-WORLD DRUG EFFECTS IN INFLAMMATORY RHEUMATIC DISEASES () - May 28, 2025 - Abstract #EULAR2025EULAR_3473;
While inter-individual variation in experiences with ESM via mHealth motivates further improvements in the ESM procedure, the acceptance of IRD patients to report patient-reported outcomes using ESM via mHealth appears good. Therefore, the application of this method in scientific research on real-world drug effects appears to be promising.
- HOW DISEASE ACTIVITY AFFECTS ULTRASONOGRAPHIC MARKERS OF ARTERIAL STIFFNESS IN RA PATIENTS TREATED WITH TNF INHIBITORS AND JAK INHIBITORS () - May 28, 2025 - Abstract #EULAR2025EULAR_3472;
This relationship was not observed with DAS28-ESR or DAS28-CRP. These findings may reflect distinct anti-inflammatory effects of TNF and JAK inhibitors.
- Idacio (adalimumab-aacf) / Fresenius Kabi, Humira (adalimumab) / AbbVie
USE OF FK-ADA BIOSIMILAR (MSB 11022) IN CONTEXT OF BIOLOGIC SWITCH IN INFLAMMATORY RHEUMATIC DISEASES: 6 MONTHS DATA OF THE REAL-WORLD EUROPEAN STUDY IDEA () - May 28, 2025 - Abstract #EULAR2025EULAR_3470;
The observed high persistence rate under FK-ada was related to stable (PsA) or even improved (RA and AS) response rates. The safety profile was as expected for this population.
- Idacio (adalimumab-aacf) / Fresenius Kabi, Humira (adalimumab) / AbbVie
THREE YEARS REAL WORLD PERSISTENCE DATA OF FRESENIUS KABI () - May 28, 2025 - Abstract #EULAR2025EULAR_3465;
In general, Humira and adalimumab biosimilars to FK-ada switch showed high persistence probability at 36 months for the inflammatory arthritis diseases: RA/PsA/AS. Older aged was associated with a longer persistence probability in RA; whereas male gender for patients with PsA/AS was associated with a longer persistence probability for patients on FK-ada.
- Idacio (adalimumab-aacf) / Fresenius Kabi, Humira (adalimumab) / AbbVie
REAL WORLD PERSISTENCE DATA FOR INFLAMMATORY ARTHRITIS (IA) PATIENTS TREATED WITH FRESENIUS KABI ADALIMUMAB BIOSIMILAR (FK-ada) MSB11022: SWITCHED FROM HUMIRA, ADALIMUMAB BIOSIMILARS, AND NON-ADALIMUMAB BIOLOGICS (TWO YEAR) () - May 28, 2025 - Abstract #EULAR2025EULAR_3460;
Older aged was associated with a longer persistence probability in RA; whereas male gender for patients with PsA/AS was associated with a longer persistence probability for patients on FK-ada. Overall, FK-ada treatment persistence was well maintained for Humira switched patients with IA, and was significantly higher when compared to either one adalimumab biosimilar switched (presumably due to treatment failure/intolerance), or previously switched from one or more non-adalimumab biosimilar (presumably due to treatment failure/intolerance).
- LOW INCIDENCE OF NEONATAL INFECTION WITH TNF AND NON-TNF BIOLOGIC DMARD USE IN THE SECOND AND THIRD TRIMESTERS OF PREGNANCY () - May 28, 2025 - Abstract #EULAR2025EULAR_3443;
In this single center study, the late exposure to biologics in pregnancy yielded a very low incidence of infection in newborns to mothers with autoimmune conditions. The results of this study support the most recent 2024 EULAR Update in taking a more permissive approach to the continuation of biologics in pregnancy for the treatment of autoimmune diseases.
- ARE THERE MORE ADVERSE EVENTS AND ADVERSE REACTIONS REPORTED WITH ANTITNFs OR JAK INHIBITORS REGISTRY OF THE PHARMACOVIGILANCE PROGRAM IN A SPECIALIZED CENTER OF RHEUMATOLOGY () - May 28, 2025 - Abstract #EULAR2025EULAR_3384;
This study shows that cardiovascular adverse events are more frequent with anti-TNFs. On the other hand, DVT events are rare, but more frequent with JAKinibs.
- Remicade (infliximab) / J&J, Simponi (golimumab) / J&J, Humira (adalimumab) / AbbVie
MONOCLONAL ANTI-TUMOR NECROSIS FACTOR-ALPHA ANTIBODIES FOR VASCULAR BEH () - May 28, 2025 - Abstract #EULAR2025EULAR_3349;
Prevention of relapses and control of disease progression remain critical goals in managing VBS. To further validate their efficacy, RCTs stratified by arterial and venous involvement are warranted.
- Yuflyma (adalimumab-aaty) / Celltrion, Hikma
SEX DIFFERENCES ASSOCIATED WITH OVERALL TOLERANCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR, A POST-HOC ANALYSIS FROM THE YU-MATTER STUDY () - May 28, 2025 - Abstract #EULAR2025EULAR_3284;
P
This post-hoc analysis showed that women switching to CT-P17 were globally satisfied; however, women experienced higher pain and lower overall tolerance. This difference should be considered in day-to-day management to help the physician to prevent the nocebo effect in women, and specific studies should focus on this point.
- || Olumiant (baricitinib) / Eli Lilly
Trial completion date, Trial primary completion date: RA-BRANCH: A Study of Baricitinib in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - May 28, 2025
P4, N=1300, Recruiting, Sponsor: Eli Lilly and Company
This difference should be considered in day-to-day management to help the physician to prevent the nocebo effect in women, and specific studies should focus on this point. Trial completion date: Apr 2026 --> May 2025 | Trial primary completion date: Apr 2026 --> May 2025
- | Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date: COMET: Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial (clinicaltrials.gov) - May 28, 2025
P3, N=166, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Trial completion date: Apr 2026 --> May 2025 | Trial primary completion date: Apr 2026 --> May 2025 Trial completion date: Mar 2024 --> May 2027 | Trial primary completion date: Aug 2023 --> Aug 2026
- || Review, Journal: JAK-STAT inhibitors in noninfectious uveitis - A review. (Pubmed Central) - May 28, 2025
inhibitors, such as adalimumab and infliximab...JAK-STAT inhibitors, such as tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib have been FDA-approved for use in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and inflammatory bowel disease. The available literature suggests the potential efficacy of these drugs in controlling uveitic inflammation; however, their use in NIU is still under investigation, with no randomized controlled trials providing Level I evidence.
- | Retrospective data, Journal: Failure of primary immunosuppressive agents in uveitis. (Pubmed Central) - May 28, 2025
The use of biologics like Tofa, especially in VKH, can be a valuable treatment option. Future prospective studies with larger cohorts are needed to validate these findings and explore the disease-specific effectiveness of IMT regimens.
- | methotrexate / Generic mfg., mycophenolate mofetil / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Uveitis in Adults: A Review. (Pubmed Central) - May 28, 2025
For posterior noninfectious uveitis, disease-modifying antirheumatic drugs are first-line therapy; biologics such as adalimumab are second-line treatment for patients with inflammation refractory to treatment. Uveitis caused by systemic infection should be treated with antimicrobials, and local or systemic steroids may be used depending on the severity of uveitis and the specific microorganism.
- | Humira (adalimumab) / AbbVie
Journal: Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study. (Pubmed Central) - May 27, 2025
None of the three patients who showed initial improvement in visual acuity had any baseline cystoid macular edema or vitreous haze to account for the improvement in BCVA. Subconjunctival administration of 5?mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.
- | Retrospective data, Journal: Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China. (Pubmed Central) - May 27, 2025
Our findings suggest that dual-target therapy demonstrates promising efficacy and an acceptable safety profile in refractory IBD patients. DTT may represent a valuable therapeutic option for patients who have not responded to conventional monotherapies.
- | Simponi (golimumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Retrospective data, Journal: The Relationship Between TNF-? Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. (Pubmed Central) - May 26, 2025
High-potency TNF-? inhibitors significantly increase HBV reactivation risk in HBsAg+ patients, while HBsAg-/HBcAb+ patients have a uniformly low risk across all inhibitors.
- | methotrexate / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Lingual Dystonia Following Thalamic Infarction in a Patient on Methotrexate Therapy for Hidradenitis Suppurativa. (Pubmed Central) - May 26, 2025
The finding of thalamic infarction on brain CT and the lack of clinical improvement in dystonia symptoms after prolonged MTX withdrawal from therapy indicate that lingual dystonia could be directly causally related to thalamic insult, while it is less likely that lingual dystonia is a side effect of MTX therapy. This case provides us with new knowledge in determining the etiology of lingual dystonia in the light of thalamic infarction and MTX neurotoxicity.
- | Humira (adalimumab) / AbbVie
Biomarker, Journal: Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response. (Pubmed Central) - May 26, 2025
This study advances the understanding of transcriptomic alterations in RA treatment and enhancing our understanding of treatment response mechanisms. Whilst the gene signatures identified require independent replication, the study serves as a starting point to pave the way for personalized therapeutic strategies in patients commencing TNFi therapy in RA.
- ||| Journal, Adverse events: Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database. (Pubmed Central) - May 25, 2025
Immunosuppressants and monoclonal antibodies show mild trends in DIP occurrence. Additionally, adalimumab, adapalene, secukinumab, and fingolimod are novel drug signals of DIP.
- | Humira (adalimumab) / AbbVie
Journal: m6A modification profiles of the CHO cells with differential recombinant protein expression using MeRIP-seq/RNA-seq. (Pubmed Central) - May 25, 2025
In this study, through m6A-specific methylated RNA immunoprecipitation sequencing (MeRIP-seq) of high- (ADM-H) and low- (ADM-L) recombinant adalimumab (ADM)-producing CHO cell lines, we identified 668 differentially methylated peaks...Furthermore, pharmacological inhibition of Gli2 or Met in cell culture effectively enhanced ADM production while suppressing target gene expression. These findings elucidate m6A's functional role in recombinant protein production and provide actionable strategies for CHO cell line optimization.
- || Review, Journal: Ustekinumab in the Treatment of Crohn's Disease-A Narrative Review on Clinical Efficacy and Safety Profile. (Pubmed Central) - May 23, 2025
The analysis of predictive biomarkers, such as serum drug levels and baseline eosinophil levels, could be an important element in the future personalization of CD treatment. The review's findings point to the importance of further research to improve the tailoring of therapies to individual patients and improve long-term treatment outcomes.
- | Humira (adalimumab) / AbbVie
Journal: Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab. (Pubmed Central) - May 23, 2025
In HS patients with suboptimal response to standard adalimumab dosing, a significant number of patients have subtherapeutic drug levels with a minority of those having anti-adalimumab antibodies. TDM can be helpful in identifying HS patients with subtherapeutic drug levels and without antidrug antibodies who could potentially benefit from dose escalation.
- | thalidomide / Generic mfg.
Journal: Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report. (Pubmed Central) - May 22, 2025
This report shows that thalidomide should be considered a potential cause of CNS demyelination, similar to biologic TNF-? inhibitors, and should be avoided in patients with a heightened risk.
- | Journal: Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Cohort. (Pubmed Central) - May 22, 2025
The most frequent biologics at enrolment were adalimumab and ustekinumab, however, this has changed with the introduction of new and more effective therapies. BADBIR is a rich data providing information on the management of psoriasis.
- | Journal: Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation. (Pubmed Central) - May 21, 2025
The time to discontinuation for reasons other than efficacy was significantly shorter for cIMT as compared to bIMT (p?<?0.0001). Similar to findings in other inflammatory diseases, bIMT was better tolerated than cIMT in the treatment of ocular inflammation.
- | Humira (adalimumab) / AbbVie
Journal: Massive Malignant Transformation in a Patient with Hidradenitis Suppurativa during Anti-Tumor Necrosis Factor Treatment. (Pubmed Central) - May 21, 2025
This report details the case of a 53-year-old man with a history of HS treatment with adalimumab and systemic antibiotics who developed well-differentiated SCC...Follow-up showed no disease progression. This case highlights the importance of early detection, routine screening, and a multidisciplinary approach in managing the risk of SCC in patients with HS.
- || Entyvio (vedolizumab) / Takeda
Retrospective data, Review, Journal: Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-? in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis. (Pubmed Central) - May 20, 2025
Real-world use of vedolizumab was associated with favourable long-term effectiveness and treatment persistence. Vedolizumab is a suitable first-line biological option for biologic-naive patients with CD.
- | Journal, Real-world evidence, Real-world: Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment. (Pubmed Central) - May 20, 2025
Vedolizumab is a suitable first-line biological option for biologic-naive patients with CD. This study identifies paradoxical IBD as a consistent positive signal across multiple IMID agents, predominantly manifesting as CD, potentially aiding in timely detection and therapeutic decision-making.
- || Biomarker, Review, Journal: Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review. (Pubmed Central) - May 20, 2025
Our analysis spans multiple omics disciplines, including genomics, transcriptomics (both bulk RNA and single-cell RNA sequencing), proteomics, microbiomics, and metabolomics, with particular emphasis on the impact of models integrating multiple omics datasets. Additionally, to further the field of precision medicine, we evaluated specific biomarkers that may exhibit distinct effects on responses to multiple therapeutic interventions.
- || Olumiant (baricitinib) / Eli Lilly
Trial completion date: RA-BRIDGE: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - May 20, 2025
P4, N=2600, Active, not recruiting, Sponsor: Eli Lilly and Company
Additionally, to further the field of precision medicine, we evaluated specific biomarkers that may exhibit distinct effects on responses to multiple therapeutic interventions. Trial completion date: Feb 2026 --> May 2025
- | Humira (adalimumab) / AbbVie
Journal: The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report. (Pubmed Central) - May 20, 2025
inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.
- ||| Journal, Adverse events: Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry. (Pubmed Central) - May 19, 2025
In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy. Our data support that, overall, the new biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars.
- | Journal: Antitumor Necrosis Factor-Refractory Esophageal Lesions in Crohn's Disease Successfully Treated With Upadacitinib. (Pubmed Central) - May 19, 2025
Consequently, all esophageal lesions were healed, and serum biomarkers returned negative results. Although upadacitinib is effective for patients with ileocolonic Crohn's disease, this is the first case demonstrating its efficacy for refractory esophageal lesions.
- | prednisone / Generic mfg., Humira SC (adalimumab/hyaluronidase) / AbbVie, Humira (adalimumab) / AbbVie
Journal: Association of tattoos with cutaneous sarcoidosis and anterior uveitis. (Pubmed Central) - May 17, 2025
This is likely due to a combination of exaggerated inflammatory responses and granuloma formation at tattoo sites from a chronic foreign body reaction or immune activation. We present a case of tattoo-associated cutaneous sarcoidosis with uveitis in which the patient had an elevated ACE level and was successfully treated with prednisone eye drops and weekly subcutaneous adalimumab.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Proactive Drug Monitoring versus Clinically-based Dosing for Endoscopic Healing in Pediatric Crohn's Disease Receiving Infliximab. (Pubmed Central) - May 17, 2025
We present a case of tattoo-associated cutaneous sarcoidosis with uveitis in which the patient had an elevated ACE level and was successfully treated with prednisone eye drops and weekly subcutaneous adalimumab. Dosing based on proactive TDM was superior to clinically-based dosing in terms of EH in a randomized controlled trial of pediatric CD.
- || Tremfya (guselkumab) / J&J
Retrospective data, Review, Journal: One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis. (Pubmed Central) - May 17, 2025
Dosing based on proactive TDM was superior to clinically-based dosing in terms of EH in a randomized controlled trial of pediatric CD. Results of this NMA in moderately to severely active CD indicate a higher likelihood of guselkumab achieving each clinical and endoscopic endpoint analyzed at the end of the maintenance phase versus other advanced therapies assessed.
- Statistical Analysis of Drug-Induced Gastric Cancer: A Review of Reports from FAERS () - May 16, 2025 - Abstract #IGCC2025IGCC_524;
This study highlights the risks of drug-induced gastric cancer, particularly concerning the potential impacts of antacids, immunosuppressants, and anticoagulants. Future research is recommended focus on the long-term use of these medications and their impact alongside enhancing regulatory oversight and monitoring of drug use to mitigate the burden of drug-induced gastric cancer.
- | Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis. (Pubmed Central) - May 16, 2025
Future research is recommended focus on the long-term use of these medications and their impact alongside enhancing regulatory oversight and monitoring of drug use to mitigate the burden of drug-induced gastric cancer. CZP may be more effective than Fc?containing TNFi in patients with RA and high RF levels.
- || Review, Journal: Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence. (Pubmed Central) - May 16, 2025
CZP may be more effective than Fc?containing TNFi in patients with RA and high RF levels. This review analyses the
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Efficacy of Anti-TNF-? Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series. (Pubmed Central) - May 16, 2025
These findings support the utility of anti-TNF-? inhibitors in the management of refractory leg ulcers in cPAN, highlighting the need for further large-scale studies to validate the results.
- | Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Efficacy and safety of biologics in pediatric non-infectious retinal vasculitis. (Pubmed Central) - May 16, 2025
TCZ appears as an effective therapy for patients with JIA-associated RV or those who failed TNF-? inhibitors.
- | Journal: Cancer and Hidradenitis Suppurativa. (Pubmed Central) - May 16, 2025
Other factors that have occasionally been associated with hidradenitis suppurativa-related squamous cell carcinoma include treatment with a tumor necrosis factor-alpha inhibitor (such as infliximab and adalimumab), genodermatoses (such as keratitis-ichthyosis-deafness syndrome and Dowling-Degos disease), and paraneoplastic syndromes (such as hypercalcemia, hypercalcemia-leukocytosis, and paraneoplastic neuropathy)...The potential role of human papillomavirus vaccination for cancer prevention and early treatment of squamous cell carcinoma with targeted therapy (with an epidermal growth factor inhibitor such as cetuximab) and/or checkpoint inhibitor immunotherapy (such as cemiplimab and pembrolizumab) remains to be determined...Also, both primary cancers (such as cutaneous squamous cell carcinoma and mucinous adenocarcinoma) and breast cancer skin metastases can masquerade as hidradenitis suppurativa lesions. For these reasons, when a lesion is located at a current or prior site of hidradenitis suppurativa that is new or rapidly growing and/or does not respond to hidradenitis suppurativa-directed therapy, prompt evaluation to establish or exclude the diagnosis of cancer should be considered.
- || Review, Journal: Report and literature review of a familial case of autoinflammatory disease associated with RELA gene variant (Pubmed Central) - May 15, 2025
The nonsense variant c.985C>T (p.Arg329Ter) in the RELA gene is likely the genetic cause of the child's recurrent fever, vomiting, and oral ulcers. WES is valuable for timely diagnosis of RAID and provides a basis for clinical treatment strategies.
- | Journal, Real-world evidence: Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study. (Pubmed Central) - May 15, 2025
Only 26.7% of patients remained on first bDMARD after 50 months, with those receiving RTX less likely to discontinue for any reason. RF and/or ACPA positivity could be potential risk factors for discontinuation due to AEs or inefficacy.
- ||| Retrospective data, Journal, Adverse events, Real-world evidence: Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study. (Pubmed Central) - May 15, 2025
Doctors need to pay close attention to the appearance of mycobacterial infectious disorders in older adults treating with TNF-? inhibitors, which displayed the strongest signal.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy. (Pubmed Central) - May 15, 2025
inhibitors, which displayed the strongest signal. Patients with HS on anti-TNF therapy receiving the SARS-CoV-2 mRNA vaccine seroconvert similarly as those without anti-TNF therapy, indicating this population should receive the vaccine and expect a similar degree of protection against COVID-19 compared to HS patients who do not receive anti-TNF therapy.
- | methotrexate / Generic mfg., Humira (adalimumab) / AbbVie, cyclosporine / Generic mfg.
Journal: Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA). (Pubmed Central) - May 14, 2025
The PSORSA registry provides valuable insights into the demographics, clinical characteristics, and treatment patterns of patients with psoriasis in Saudi Arabia. These findings emphasize the need for real-world data to guide regional psoriasis management strategies.
- | Humira (adalimumab) / AbbVie
Journal: Risk of adalimumab-induced psoriasis in hidradenitis suppurativa versus other inflammatory diseases. (Pubmed Central) - May 14, 2025
These findings emphasize the need for real-world data to guide regional psoriasis management strategies. No abstract available